Qiagen N.v
Qiagen N.v (QGEN) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Venlo, Netherlands and has 5,500 employees. The company is worth $10.37B and trades at 25.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.09B in fiscal 2025, up 5.7% from the year before. Net income was $424.88M. The share price is 13.1% below its 52-week high of $57.82. It pays a dividend yielding 0.70%. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $150.36M. In that quarter, 4 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -18.9% over 5Y.
today you would have $838.28▼ -16.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $44.97 | $44.53 | $44.82 | $51.47 | $57.36 | $54.54 | $34.88 | $35.55 | $31.92 | $30.06 | $29.66 | $25.17 | $25.54 | $19.47 | $14.81 | $20.97 | $23.95 | $18.84 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 4.9% a year plus a 0.7% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 36.0 across this company’s own years on record.
Cash flow growing 4.9% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENSGEnsign Group Inc | $178.35 | 27.2x | 4.2x | 0.15% | 16.97% | $10.39B |
| GKOSGLAUKOS Corp | $176.69 | — | 15.2x | 0.00% | -25.98% | $10.42B |
| OSCROscar Health, Inc. | $33.32 | 26.0x | 5.0x | 0.00% | 34.26% | $10.28B |
| PODDInsulet Corp | $148.12 |
| P/E | 36.0x | 23.2x | 120.4x | 30.3x | 28.0x | 26.0x | 35.6x | — | 43.4x | 187.8x | 88.4x | 53.9x | 52.4x | 84.7x | 34.7x | 35.6x | 33.6x | 36.0x | 41.2x |
| P/S | 5.2x | 4.7x | 5.1x | 5.3x | 5.5x | 5.9x | 6.8x | 5.2x | 5.5x | 5.2x | 5.4x | 5.5x | 4.5x | 4.6x | 3.5x | 2.9x | 0.0x | 5.3x | 4.1x |
| P/B | 2.7x | 2.6x | 2.8x | 2.7x | 3.4x | 4.3x | 4.6x | 3.1x | 3.1x | 2.9x | 2.8x | 2.8x | 2.3x | 2.2x | 1.6x | 1.3x | 0.0x | 2.3x | 2.5x |
| EPS | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 | $1.53 | -$0.18 | $0.82 | $0.17 | $0.34 | $0.55 | $0.48 | $0.30 | $0.56 | $0.42 | $0.62 | $0.67 | $0.46 |
| Dividend yield | 3.05% | 0.56% | 3.05% | — | — | — | — | — | — | 3.61% | — | — | — | — | — | — | — | — | — |
| Payout | 366.96% | 12.89% | 366.96% | — | — | — | — | — | — | 678.74% | — | — | — | — | — | — | — | — | — |
| Profit margin | 10.24% | 20.33% | 4.23% | 17.37% | 19.76% | 22.77% | 19.20% | -2.72% | 12.68% | 2.85% | 6.01% | 10.16% | 8.65% | 5.31% | 10.32% | 8.21% | 13.27% | 13.64% | 9.97% |
| ROE | 5.45% | 11.25% | 2.34% | 8.96% | 12.21% | 16.55% | 12.84% | -1.63% | 7.23% | 1.59% | 3.08% | 5.07% | 4.39% | 2.54% | 4.77% | 3.77% | 5.83% | 6.01% | 6.12% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-28.4% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 27.7x |
| 7.2x |
| 0.00% |
| 26.02% |
| $10.27B |
| MDGLMadrigal Pharmaceuticals Inc | $453.34 | — | 20.0x | 0.00% | -53.31% | $10.47B |
| PCVXVaxcyte, Inc. | $62.85 | — | 3.3x | 0.00% | -36.51% | $9.89B |